Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31109671 | 1.00 | RAB9A (0.48) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL31194832 | 0.98 | RAB9A (0.47) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2666929 | 0.78 | RAB9A (0.42) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL805088 | 0.78 | SMN1; SMN2 (0.42) | RAB9AMAPTSMN1; SMN2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL29733282 | 0.77 | SMN1; SMN2 (0.41) | RAB9AMAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL113113 | 0.75 | RAB9A (0.40) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL558903 | 0.75 | AXL (0.48) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL11999657 | 0.75 | RAB9A (0.40) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30136461 | 0.75 | RAB9A (0.40) | RAB9AMAPTPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19454408 | 0.75 | CYP1A2 (0.36) | RAB9AMAPTSMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| WO-2022270881-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| US-8178555-B2 | Apoptosis signal-regulating kinase 1 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2007058482-A1 | NOVEL INHIBITORS OF PROTEIN KINASE | LG LIFE SCIENCES, LTD. (KR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | RAB9A 2032/4885MAPT 2356/4885PIK3CD 2635/4885 |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NR3C2, RAF1 | RAB9A 1543/4885MAPT 4487/4885PIK3CD 1257/4885 |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | RAB9A 3465/4885MAPT 1024/4885PIK3CD 471/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | RAB9A 2032/4885MAPT 2356/4885PIK3CD 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.